On May 21, 2026, Assembly Biosciences, Inc. (the "Company") entered into an underwriting agreement (the "Underwriting Agreement") with Guggenheim Securities, LLC ("Guggenheim Securities") and UBS Sec…
On May 21, 2026, Assembly Biosciences, Inc. (the "Company") entered into an underwriting agreement (the "Underwriting Agreement") with Guggenheim Securities, LLC ("Guggenheim Securities") and UBS Sec…
Assembly Biosciences, Inc. Customers
No clients on recordNo downstream customers found in our database for Assembly Biosciences, Inc..
Assembly Biosciences, Inc. Debt Obligations
Instrument
Description
Confidence
Evidence
ASMB-DEBT-7882
Xbrl Convertible
90%
xbrl convertible detail from xbrl 2013-12-31.
ASMB-DEBT
Debt stack $2.5M
90%
Market cache reports total debt of $2.5M.
ASMB-DEBT-7881
Warrants outstanding: 1040820
90%
xbrl warrant detail from xbrl 2025-12-31.
Assembly Biosciences, Inc. Acquisitions
No acquisitions on recordNo completed or pending acquisitions found in our database for Assembly Biosciences, Inc..
Assembly Biosciences, Inc. Ownership
Holder
Name
Confidence
Evidence
ASMB-OWNER-GILEAD-SCIENCES-INC
GILEAD SCIENCES, INC.
90%
13F overlay lists GILEAD SCIENCES, INC. as top holder; 75 tracked holders.
Assembly Biosciences, Inc. Extended Supply Chain Network